ClinConnect ClinConnect Logo
Search / Trial NCT06496178

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients

Launched by MERUS N.V. · Jul 3, 2024

Trial Information

Current as of July 23, 2025

Recruiting

Keywords

Hnscc

ClinConnect Summary

This clinical trial is studying a new treatment called petosemtamab for patients with head and neck squamous cell carcinoma (HNSCC) who have already received other treatments. It aims to find out if petosemtamab is more effective than the treatment chosen by the doctor for patients whose cancer has returned or spread and cannot be cured with standard therapies. The trial is open to adults aged 18 and older who have been diagnosed with advanced HNSCC and have shown that their cancer progressed after receiving previous treatments, including certain immunotherapy and chemotherapy.

To participate, patients need to have measurable cancer that can be assessed by imaging tests and meet specific health criteria, such as not having serious ongoing illnesses or complications from past cancer treatments. Participants will receive either petosemtamab or the doctor's choice of treatment and will be monitored throughout the study. This trial is currently recruiting new participants, and it's important for anyone interested to discuss with their healthcare provider to see if they qualify and to understand what taking part might involve.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Signed ICF before initiation of any study procedures.
  • Age ≥ 18 years at signing of ICF.
  • Histologically previously confirmed HNSCC with evidence of metastatic or locally advanced disease not amenable to standard therapy with curative intent.
  • HNSCC patients progressed on or after anti-PD-1 therapy and platinum-containing therapy.
  • The eligible HNSCC primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx.
  • Documentation of p16 status (positive or negative) by local laboratory IHC for patients with primary oropharyngeal cancer.
  • A baseline new tumor sample unless the patient has an available tumor sample as an FFPE block with sufficient material.
  • Measurable disease as defined by RECIST v1.1 by radiologic methods.
  • ECOG PS of 0 or 1
  • Life expectancy ≥ 12 weeks, as per investigator
  • Adequate organ function (as per protocol)
  • Exclusion Criteria:
  • Central nervous system metastases that are untreated or symptomatic, or require radiation, surgery, or continued steroid therapy to control symptoms within 14 days of study entry.
  • Known leptomeningeal involvement
  • Any systemic anticancer therapy within 4 weeks of the first dose of study treatment.
  • Major surgery or radiotherapy within 3 weeks of the first dose of study treatment.
  • Persistent Grade \>1 clinically significant toxicities related to prior antineoplastic therapies
  • History of hypersensitivity reaction to any of the excipients of treatment required for this study.
  • Unstable angina; history of congestive heart failure of Class II-IV New York Heart Association (NYHA) criteria, or serious cardiac arrhythmia requiring treatment or history of myocardial infarction within 6 months of study entry
  • History of prior malignancies with the exception of excised cervical intraepithelial neoplasia or nonmelanoma skin cancer, or curatively treated cancer deemed at low risk for recurrence with no evidence of disease
  • Current dyspnea at rest of any origin, or other diseases requiring continuous oxygen therapy
  • Current serious illness or medical conditions including, but not limited to, uncontrolled active infection, clinically significant pulmonary, metabolic or psychiatric disorders
  • Patients with known infectious diseases (as per protocol)
  • Pregnant or breastfeeding patients
  • Patient has a primary tumor site of nasopharynx (any histology).

About Merus N.V.

Merus N.V. is a clinical-stage biopharmaceutical company dedicated to advancing innovative therapeutic solutions for patients with cancer. Utilizing its proprietary antibody technology platform, Merus specializes in the development of bispecific antibodies designed to target multiple pathways in tumor biology, enhancing efficacy while minimizing toxicities. With a robust pipeline of drug candidates undergoing various stages of clinical trials, Merus is committed to addressing unmet medical needs in oncology and improving patient outcomes through cutting-edge science and strategic partnerships. The company is headquartered in Utrecht, Netherlands, and focuses on translating groundbreaking research into meaningful therapies for patients worldwide.

Locations

Detroit, Michigan, United States

Louisville, Kentucky, United States

Houston, Texas, United States

Salt Lake City, Utah, United States

Spokane, Washington, United States

Darlinghurst, , Australia

Jerusalem, , Israel

Tel Aviv, , Israel

Bradenton, Florida, United States

Orlando, Florida, United States

Saint Louis, Missouri, United States

Albuquerque, New Mexico, United States

Blacksburg, Virginia, United States

Saint Leonards, , Australia

Providencia, , Chile

Tel Hashomer, , Israel

Goyang Si, , Korea, Republic Of

Kaohsiung, , Taiwan

New York, New York, United States

Cincinnati, Ohio, United States

Charlottesville, Virginia, United States

Recoleta, , Chile

Santiago, , Chile

Haifa, , Israel

La Jolla, California, United States

Palo Alto, California, United States

Portland, Oregon, United States

Nedlands, Western Australia, Australia

Santiago, , Chile

Hwasun, Jeollanam Do, Korea, Republic Of

Indianapolis, Indiana, United States

Columbus, Ohio, United States

El Paso, Texas, United States

Buenos Aires, , Argentina

Seoul, , Korea, Republic Of

Soeul, , Korea, Republic Of

Taipei City, , Taiwan

Baton Rouge, Louisiana, United States

Córdoba, , Argentina

Melbourne, , Australia

Changhua, , Taiwan

Taipei, , Taiwan

Liverpool, , United Kingdom

London, , United Kingdom

Sutton, , United Kingdom

San Francisco, California, United States

Maple Grove, Minnesota, United States

Charleston, South Carolina, United States

Houston, Texas, United States

Seoul, , Korea, Republic Of

Taoyuan City, , Taiwan

Manchester, , United Kingdom

Taichung, , Taiwan

Chicago, Illinois, United States

Chattanooga, Tennessee, United States

Memphis, Tennessee, United States

Nashville, Tennessee, United States

Nashville, Tennessee, United States

Denison, Texas, United States

Capital Federal, , Argentina

Viedma, , Argentina

Brussel, , Belgium

Namur, , Belgium

Greifswald, , Germany

Nijmegen, , Netherlands

Utrecht, , Netherlands

Madrid, , Spain

Pamplona, , Spain

Pamplona, , Spain

Cambridge, , United Kingdom

Middlesex, , United Kingdom

Madrid, , Spain

Valencia, , Spain

Duarte, California, United States

La Jolla, California, United States

Fort Myers, Florida, United States

Boston, Massachusetts, United States

Ciudad Autonoma De Buenos Aires, , Argentina

Darlinghurst, , Australia

Sydney, , Australia

Leuven, , Belgium

Recoleta, , Chile

Santiago, , Chile

Gießen, , Germany

Hamburg, , Germany

Thessaloníki, , Greece

Jerusalem, , Israel

Tel Aviv, , Israel

Milano, , Italy

Rozzano, , Italy

Amsterdam, , Netherlands

Barcelona, , Spain

Taipei, , Taiwan

Hackensack, New Jersey, United States

Cleveland, Ohio, United States

Caba, , Argentina

Nedlands, , Australia

Gent, , Belgium

Hamburg, , Germany

Athens, , Greece

Brescia, , Italy

Napoli, , Italy

Hwasun, , Korea, Republic Of

London, , United Kingdom

Prescott, Arizona, United States

Washington, District Of Columbia, United States

New Orleans, Louisiana, United States

Ann Arbor, Michigan, United States

Chapel Hill, North Carolina, United States

Pearland, Texas, United States

Rosario, , Argentina

Liège, , Belgium

Bordeaux, , France

Marseille, , France

Montpellier, , France

Paris, , France

Rouen, , France

Villejuif, , France

Aachen, , Germany

Hannover, , Germany

Leipzig, , Germany

Würzburg, , Germany

Athens, , Greece

Cuneo, , Italy

Gliwice, , Poland

Madrid, , Spain

Kaohsiung City, , Taiwan

Scottsdale, Arizona, United States

Sacramento, California, United States

Jacksonville, Florida, United States

Rochester, Minnesota, United States

Durham, North Carolina, United States

Brussels, , Belgium

Lyon, , France

Toulouse, , France

Berlin, , Germany

Heraklion, , Greece

Río, , Greece

Milano, , Italy

Skorzewo, , Poland

Lone Tree, Colorado, United States

Poitiers, , France

Chuo Ku, , Japan

Kashiwa, , Japan

Miki, , Japan

Sendai, , Japan

ōsaka Sayama, , Japan

Seoul, , Korea, Republic Of

Temple Terrace, Florida, United States

Rennes, , France

Vandœuvre Lès Nancy, , France

Nagoya, , Japan

Gdańsk, , Poland

London, , United Kingdom

Porto Alegre, , Brazil

Porto Alegre, , Brazil

Recife, , Brazil

Rio De Janeiro, , Brazil

São Paulo, , Brazil

São Paulo, , Brazil

Lille, , France

Chicago, Illinois, United States

Columbia, Maryland, United States

Bensalem, Pennsylvania, United States

Brasília, , Brazil

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported